GI INNOVATION, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,000 KRW | -0.08% |
|
+1.01% | +7.88% |
| 2023 | GI Innovation, Inc.(KOSDAQ:A358570) added to S&P Global BMI Index | CI |
| 2023 | GI Innovation, Inc. has completed an IPO in the amount of KRW 26 billion. | CI |
| 1 day | -0.08% | ||
| 1 week | +1.01% | ||
| Current month | -1.07% | ||
| 1 month | -1.29% | ||
| 3 months | +28.08% | ||
| 6 months | +37.86% | ||
| Current year | +7.88% |
1 week
12 610.00
13 950.00
1 month
12 460.0014 250.00
Current year
9 810.0014 650.00
1 year
8 080.0015 700.00
3 years
8 080.0015 700.00
5 years
8 080.0015 700.00
10 years
8 080.0015 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jun-Ho Hong
CEO | Chief Executive Officer | 52 | - |
Byeong-Geon Lee
CEO | Chief Executive Officer | 67 | 03/03/22 |
Jin-Man Kim
DFI | Director of Finance/CFO | 42 | 31/08/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Byeong-Geon Lee
CEO | Chief Executive Officer | 67 | 03/03/22 |
Su-Yeon Nam
PSD | President | 58 | 30/11/18 |
Geun-Yong An
BRD | Director/Board Member | 49 | 28/02/22 |
GI Innovation Inc is a Korea-based company engaged in the research and development of next-generation immunotherapies based on fusion proteins. The Company is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.
Calendar
11/08/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +7.88% | 420M | |
| +64.92% | 62.59B | |
| -1.85% | 41.18B | |
| +44.76% | 40.29B | |
| -8.93% | 27.9B | |
| +13.05% | 26.21B | |
| -21.96% | 19.09B | |
| +4.21% | 13.08B | |
| +25.74% | 12.26B | |
| +27.42% | 12.05B |
- Stock Market
- Equities
- A358570 Stock
